

# COPY

**CLEAN VERSION OF EACH REPLACEMENT PARAGRAPH/SECTION/CLAIM AND**  
**INSTRUCTIONS FOR ENTRY**

**IN THE SPECIFICATION:**

As a result of these procedures, the disease specific markers (Y14737) immunoglobulin lambda heavy chain and (X91133) immunoglobulin lambda chain variable region related to Alzheimers disease were found. Marker (Y14737) immunoglobulin lambda heavy chain has a molecular weight of about 1286.6745 daltons and a sequence of -SEQ ID NO: 1. Marker (X91133) immunoglobulin lambda chain variable region has a molecular weight of about 1693.9237 daltons and a sequence of SEQ ID NO: 2 related to Alzheimers disease.

**IN THE CLAIMS:**

Claim 1. A biopolymer marker selected from the group consisting of SEQ ID NO: 1 or SEQ ID NO: 2 or at least one analyte thereof useful in indicating at least one particular disease state.

Claim 18. A kit for diagnosing, determining risk-assessment, and identifying therapeutic avenues related to a disease state comprising:

at least one biochemical material which is capable of specifically binding with a biomolecule which includes at least one biopolymer marker selected from the group consisting of SEQ ID NO: 1 or SEQ ID NO: 2 or at least one analyte thereof related to said disease state; and

means for determining binding between said biochemical material and said biomolecule; whereby at least one analysis to determine a presence of a marker, analyte thereof, or a

# COPY

COPY

biochemical material specific thereto, is carried out on a sample.

Claim 29. Polyclonal antibodies produced against a marker sequence ID selected from the group consisting of SEQ ID NO: 1 or SEQ ID NO: 2 or at least one analyte thereof in at least one animal host.

Claim 30. An antibody that specifically binds a biopolymer including a marker selected from the group consisting of SEQ ID NO: 1 or SEQ ID NO: 2 or at least one analyte thereof.

Claim 33. A process for identifying therapeutic avenues related to a disease state comprising:

conducting an analysis as provided by the kit of claim 18; and

interacting with a biopolymer selected from the group consisting of SEQ ID NO: 1 or SEQ ID NO: 2 or at least one analyte thereof;

whereby therapeutic avenues are developed.

Claim 34. The process for identifying therapeutic avenues related to a disease state in accordance with claim 33, wherein said therapeutic avenues regulate the presence or absence of the biopolymer selected from the group consisting of SEQ ID NO: 1 or SEQ ID NO: 2 or at least one analyte thereof.

Claim 38. A process for regulating a disease state by controlling the presence or absence

COPY